JVCKENWOOD USA (JKUSA) and EF Johnson Technologies (EFJohnson) announce a corporate realignment, with EFJohnson focusing on P25 technology and JKUSA leading...
By Anna Bratulic Bluebird bio is set to go private in a buyout by private equity firms Carlyle and SK Capital Partners, ending its turbulent run as a public company amid ongoing financial struggles. Once seen as a trailblazer in the gene therapy space, bluebird has faced mounting challenges, including shuttering its European operations after failed pricing talks for its products, and a warning about its financial viability three years ago. In 2024, it slashed about a quarter of its workforce to sustain key programmes, including its US$3.1-million sickle-cell disease...
Strengthens Nokia’s network API product development and go-to-market efforts By Oystein Bergmann, Bureau Chief, Scandinavia Nokia has announced that it...
By Julius Ewudo, ASEAN Region Representative In the wake of its recent acquisitions of IntegrationWorks and GoCloud, Australasian business solutions...